British American Tobacco stock rises as FDA authorization awaited for Velo nicotine pouch lineup

Traders Union
All News
Financial News
British American Tobacco gains 1.09% today

Highlights

British American Tobacco continued its share buyback, repurchasing 159,155 shares at 4,335.377 pence each for cancellation.
The company awaits FDA approval for its Velo nicotine pouch, while smoke-free products contributed 18.2% of 2025 sales and 2026 guidance is reaffirmed at the low end.
Bullish short- and medium-term momentum dominates, with a high probability of trading between GBX 4,316.00 and GBX 4,600.00 over the next week.

Buyback activity and FDA review shape sentiment, guidance remains cautious

British American Tobacco continues its share buyback program, with the latest purchase consisting of 159,155 ordinary shares at an average price of 4,335.377 pence each on April 1, 2026 — these shares are set for cancellation. The company is also awaiting FDA authorization for its Velo nicotine pouch lineup, emphasizing strong scientific evidence in its submissions. BAT recently reported that smoke-free products made up 18.2% of 2025 sales and reaffirmed 2026 guidance at the lower end of its medium-term range.

Technical support endures as intraday strength clashes with mixed signals

GBX 4,455.00 is positioned above the SMA-20 (GBX 4,384.35) and just above the SMA-50 (GBX 4,427.00), reinforcing short- and medium-term bullish sentiment, while long-term support remains solid with the SMA-200 at GBX 4,139.83. The Ichimoku Kijun at GBX 4,438.50 sits below the current price and acts as immediate support. Momentum signals are mixed: MACD on D1 remains a strong sell, but ADX is neutral, suggesting the trend lacks strength. RSI (50.68) and Stoch RSI (58.33) are neutral to slightly bullish, while CCI reads neutral overall. BBP indicates overbought conditions and buyer dominance intraday, pointing to strong near-term buying pressure. The daily gain of 1.09% occurred without a significant gap between previous close and opening, with the current price holding near today's high and volatility described as moderate. This reflects strength toward the top of the range, but note the divergence between strong intraday momentum and weaker daily MACD, highlighting some short-term uncertainty.

High probability of gains as volatility sets defined trading range

Looking ahead five trading days, the anticipated range is GBX 4,316.00 to GBX 4,600.00, reflecting typical blue-chip volatility and aligning with the current trend. The probability of further price increases is high (more than 80%), while downside is less likely. Baseline scenario: BATS consolidates between GBX 4,316.00 and GBX 4,600.00. A bullish scenario would see a sustained break above GBX 4,600.00, especially if short-term momentum persists. The bearish case involves a drop below GBX 4,316.00, potentially triggered if buyer momentum fades and support levels give way.

Viktoras Karapetjanc, Traders Union expert, sees British American Tobacco as technically and fundamentally well-supported. He highlights the ongoing buyback and strong push on smoke-free products as positives. Macro sentiment is constructive, with regulatory advances pending and stable blue-chip volatility. Karapetjanc believes short-term uncertainty is outweighed by healthy long-term structure and strong near-term demand. "With momentum favoring the bulls and fundamentals aligned, I expect BATS to consolidate higher toward GBX 4,600.00 this week."

Previously it was reported that British American Tobacco displayed a bullish bias as technical and regulatory factors pointed toward continued price recovery. The ongoing share buyback, robust positioning above key moving averages, and imminent FDA decisions now reinforce this outlook, with traders advised to monitor for a potential break above GBX 4,600.00 as an early signal of further upside.

Source of Data: BATS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.